Wall Street brokerages forecast that Revance Therapeutics Inc (NASDAQ:RVNC) will report earnings of ($0.98) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Revance Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.05) and the highest estimate coming in at ($0.89). Revance Therapeutics reported earnings per share of ($0.95) during the same quarter last year, which would suggest a negative year-over-year growth rate of 3.2%. The company is expected to issue its next quarterly earnings report on Monday, February 26th.
On average, analysts expect that Revance Therapeutics will report full-year earnings of ($3.74) per share for the current fiscal year, with EPS estimates ranging from ($3.96) to ($3.25). For the next year, analysts anticipate that the firm will report earnings of ($3.46) per share, with EPS estimates ranging from ($4.24) to ($2.84). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The firm’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.64) EPS.
RVNC has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $50.00 price objective on shares of Revance Therapeutics in a report on Tuesday, September 26th. ValuEngine downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. Piper Jaffray Companies reiterated a “buy” rating and issued a $28.00 price objective on shares of Revance Therapeutics in a report on Friday, October 27th. Guggenheim assumed coverage on shares of Revance Therapeutics in a report on Tuesday, December 5th. They issued a “buy” rating and a $42.00 price objective for the company. Finally, Mizuho raised their price target on shares of Revance Therapeutics from $37.00 to $54.00 and gave the stock a “buy” rating in a report on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $44.30.
Revance Therapeutics (NASDAQ:RVNC) traded up $0.20 during mid-day trading on Tuesday, reaching $33.95. 284,012 shares of the company’s stock were exchanged, compared to its average volume of 411,638. The firm has a market cap of $1,200.21, a P/E ratio of -8.93 and a beta of 1.62. Revance Therapeutics has a 12 month low of $18.00 and a 12 month high of $37.45.
In other news, Director Mark J. Foley purchased 20,000 shares of the business’s stock in a transaction dated Tuesday, November 7th. The stock was acquired at an average price of $26.96 per share, for a total transaction of $539,200.00. Following the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at $161,760. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO L Daniel Browne sold 7,600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the sale, the chief executive officer now owns 133,188 shares of the company’s stock, valued at approximately $3,321,708.72. The disclosure for this sale can be found here. 18.86% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in RVNC. PointState Capital LP boosted its position in shares of Revance Therapeutics by 58.5% during the 2nd quarter. PointState Capital LP now owns 438,200 shares of the biopharmaceutical company’s stock worth $11,568,000 after purchasing an additional 161,700 shares during the period. Vanguard Group Inc. boosted its position in shares of Revance Therapeutics by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock worth $24,595,000 after purchasing an additional 63,505 shares during the period. QS Investors LLC purchased a new position in shares of Revance Therapeutics during the 2nd quarter worth approximately $1,564,000. Northern Trust Corp boosted its position in shares of Revance Therapeutics by 19.9% during the 2nd quarter. Northern Trust Corp now owns 318,877 shares of the biopharmaceutical company’s stock worth $8,418,000 after purchasing an additional 52,940 shares during the period. Finally, Pura Vida Investments LLC purchased a new position in shares of Revance Therapeutics during the 3rd quarter worth approximately $1,378,000. Institutional investors and hedge funds own 76.69% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.